Loading...
•
Mar 31, 2024
AbCellera Q1 2024 Earnings Report
Reported financial results for the first quarter of 2024.
Key Takeaways
AbCellera reported a decrease in revenue to $10.0 million compared to $12.2 million in Q1 2023. Net loss was $40.6 million, or $(0.14) per share, compared to a net loss of $40.1 million, or $(0.14) per share in Q1 2023. The company had $725.3 million in total cash, cash equivalents, and marketable securities.
Announced a new collaboration with Biogen Inc. to discover antibodies for neurological conditions.
Announced a new collaboration with Viking Global Investors and ArrowMark Partners to launch new biotech companies.
Presented new data on its T-cell engager (TCE) programs at the American Association for Cancer ResearchⓇ Annual Meeting 2024.
Reported the start of three additional partner-initiated programs with downstreams to reach a cumulative total of 90 partner-initiated program starts with downstreams.
Revenue by Segment
Forward Guidance
No specific forward guidance was provided in the release.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...